Áttétes emlőrák: vizsgálatok itt: Kína

In Kína 224 Also abroad 610

224 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

2. fázisTaking people
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Where
Beijing, Hangzhou, Wuhan, Xi’an, Zhengzhou
Életkor
18 év and over
People
430 worldwide
Run by
Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00
1/2. fázisTaking people
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Where
Bengbu, Changchun, Chengdu, Chongqing, Huizhou, Nanning, Shanghai, Xi'an
Életkor
18 év and over
People
380 worldwide
Run by
BioNTech SE
See details and how to joinNCT06827236 · EU 2024-517979-20-00
1/2. fázisTaking people
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Where
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
Életkor
18 év and over
People
910 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06324357
No phaseTaking people
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Where
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wenzhou, Wuhan, Xiamen, Xi'an, Yangzhou, Zhengzhou, Zhongshan
Életkor
18 év and over
People
500
Run by
Hoffmann-La Roche
See details and how to joinNCT07347600
2/3. fázisTaking people
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Where
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, HangzhouZhejiang, Hefei, Jiangmen, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Ürümqi, Wuhan, Xi'an
Életkor
18 év and over
People
650 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Where
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen, Jinan, Jinhua, Kunming, Nanning, Shantou, Tianjin, Ürümqi, Xi'an, Xi’an, Xiangyang
Életkor
18 év and over
People
450 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00
3. fázisTaking people
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Where
Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou Fujian, Guangzhou, Harbin, Jiangmen, Ningbo, Shanghai, Shantou, Tianjin, Wuhan, Zhanjiang
Életkor
18 év and over
People
800 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00
3. fázisTaking people
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linhai, Nanchang, Nanjing, Nanning, Ürümqi, Wanzhou, Xi'an, Xiangyang, Zhengzhou
Életkor
18 év and over
People
1000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00
No phaseTaking people
A Real World Study of Sacituzumab Govitecan
Where
Shanghai
Életkor
18 év and over
People
100
Run by
Fudan University
See details and how to joinNCT06966141
2. fázisTaking people
Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer
Where
Shanghai
Életkor
18 év and over
People
140
Run by
Fudan University
See details and how to joinNCT07581795
3. fázisTaking people
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Where
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jining, Kunming, Liuzhou, Luoyang, Nanchang, Nanjing, Shandong, Shanghai, Shenyang, Shijiazhuang, Tianjin, Weifang, Wuhan, Xiamen, Xi'an, Xiangyang, Xinxiang, Zhengzhou
Életkor
18 év and over
People
788 worldwide
Run by
AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00
3. fázisTaking people
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Where
Anhui, Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqicun, Dalian, Deyang, Fuyang, Fuzhou, Guandong, Guangdong, Guangzhou, Haikou, Hangzhou, Hebei, Hubei, Hunan, Jieyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Nanchang, Nanjing, Nanning, Nanyang, Neijiang, Ningbo, Pingdingshan, Qingdao, Quanzhou, Shang’ai, Shanghai, Shanxi, Shaoyang, Shenyang, Shouguang, Sichuan, Tianjin, Ürümqi, Wenzhou, Wuhan, Wuhu, Xi Ail, Xiamen, Xinzheng, Xuzhou, Yuncheng, Zhejiang, Zhengzhou, Zhongshan, Zhumadian
Életkor
18 év and over
People
600 worldwide
Run by
LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00
No phaseNot yet taking people in Kína
Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer
Where
Wuhan
Életkor
18 év and over
People
1372
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07899047
No phaseTaking people
Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
Where
Hangzhou
Életkor
18 év and over
People
200
Run by
Zheng Yabing
See details and how to joinNCT07899099
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Where
Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Tianjin, Wuhan, Xi'an, Zhejiang
Életkor
18 év and over
People
420 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00
3. fázisNot yet taking people in Kína
A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
Where
Tianjin
Életkor
18 év to 75 év
People
1050
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07894328
3. fázisNot yet taking people in Kína
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
Where
Guangzhou
Életkor
18 év to 80 év
People
226
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07892274
1/2. fázisTaking people
A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
Where
Shanghai
Életkor
18 év to 75 év
People
528
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT06555068
No phaseNot yet taking people in Kína
Exploring Curative Model for Advanced Breast Cancer: a Single-center, Prospective Phase II Clinical Study
Where
Zhengzhou
People
147
Run by
Henan Cancer Hospital
See details and how to joinNCT07888556
2. fázisTaking people
A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer
Where
Shanghai
Életkor
18 év and over
People
120
Run by
Shanghai Best-Link Bioscience, LLC
See details and how to joinNCT07658183
3. fázisTaking people
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Where
Baoding, Beijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Wenzhou, Wuhan, Xi'an
Életkor
18 év and over
People
400 worldwide
Run by
Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00
2. fázisTaking people
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
Where
Zhengzhou
Életkor
18 év and over
People
134
Run by
Henan Cancer Hospital
See details and how to joinNCT05296577
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Where
Baoding, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanchang, Nanning, Shantou, Tianjin, Wuhan
Életkor
18 év and over
People
230 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00
2. fázisTaking people
ARX788 in HER2-positive Metastatic Breast Cancer Patients
Where
Zhengzhou
Életkor
18 év to 75 év
People
44
Run by
Henan Cancer Hospital
See details and how to joinNCT06663748
1. fázisTaking people
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Where
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shanghai, Shenyang
Életkor
18 év and over
People
433 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06120283 · EU 2023-506888-34-00